The Money Runs Ahead
The bottom line: Two companies working on psychedelic medicines saw their stock prices jump sharply today, with one rising about 9% and another 15%. Investors are betting that a big test of psilocybin — the active ingredient in magic mushrooms — for depression is about to deliver good news. But even if that good news comes, no actual approved medicine is coming this year. The money is racing ahead of the science, and that gap is where most of the risk lives.
Right now, the loudest signal is in the markets. Shares of COMPASS Pathways climbed roughly 9% today, and another company, atai, jumped over 15%. These moves are driven by anticipation. A major study testing psilocybin for hard-to-treat depression is around 86% finished, and people are positioning their bets before the results land. At the same time, the bigger machinery of government has not moved at all. The FDA — the agency that approves medicines in the United States — has not approved any psychedelic treatment, and won't this year. The DEA, which controls how tightly drugs are restricted, hasn't loosened its grip on psilocybin or MDMA either. Both of those steps require a long, fixed process that simply cannot finish in 2026, no matter how exciting the news gets.
Beneath the price jumps is an older, familiar pattern: money always arrives before proof. Investors are trying to guess the outcome of a test that hasn't reported yet. Our best read is that the study will likely hit its main target — meaning the treatment helps people more than a dummy version does. But the harder question is whether the benefit lasts. Psilocybin appears to make the brain more flexible for a while, but no one yet has clean, long-term proof of how long the relief holds. So even a "win" will probably come wrapped in questions. When that happens, expect a loud, messy public argument: supporters will cheer, skeptics will warn, and the truth — about whether the effect truly endures — will sit quietly in the middle, waiting for more data.
For the people who matter most in this story, the stock charts are background noise. A veteran who can't sleep without nightmares, a mother whose depression hasn't lifted despite years of trying every available pill — they aren't watching share prices. They're watching for a reason to hope that something real is finally coming. The most honest and most hopeful thing we can say to them today is this: the science is moving in the right direction, and the early signs are genuinely encouraging. But the safest, most lasting victory is one built on solid proof, not on excitement. A treatment that arrives a little later but actually works — and keeps working — is worth far more than a fast headline. That patience is not a delay of their hope. It is the protection of it.
The highest path available right now is steady and clear. Let the study report. Let the results be examined honestly, including the hard parts about whether the effect lasts. If it holds up, the door opens — properly, durably, in a way no one can later tear down. That is the outcome worth aiming at.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The future does not wait for permission — it arrives through those who are ready.
85%
No psychedelic therapy will get US government approval in 2026
The US drug regulator (FDA) won't officially approve psilocybin (the active compound in magic mushrooms) or MDMA-assisted therapy this year. Getting approval requires completing a massive paperwork package, a months-long government review, and a public expert panel — there simply isn't enough time in 2026 for all of that to happen. So people hoping to access these treatments through traditional clinics or insurance will keep waiting.
→ No psychedelic drug will be officially approved for medical use in the US this year — the government process is too slow, regardless of how good the science looks. (Confidence: 85%)
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No FDA approval of psilocybin or MDMA-based therapy issued in 2026. Even a positive Phase 3 readout this year requires NDA assembly, a multi-month review cycle, and likely an advisory committee. The timeline is mechanically impossible within calendar 2026 regardless of political pressure.
82%
The US government won't reclassify mushrooms or MDMA in 2026
Rescheduling means changing how strictly the government controls a drug — moving psilocybin or MDMA out of the most tightly locked-down category (Schedule I, reserved for substances with 'no medical use'). But by law, the DEA (the Drug Enforcement Administration, which polices controlled substances) can only do this after the FDA finishes its own review first. Since the FDA won't finish in 2026, the DEA can't act either. This matters because rescheduling would dramatically affect who can research, prescribe, and access these drugs.
→ Mushrooms and MDMA stay in the government's most restricted drug category through at least the end of 2026. (Confidence: 82%)
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No DEA rescheduling of psilocybin or MDMA in 2026. Rescheduling is statutorily contingent on completed FDA action plus a formal DEA scientific review, neither of which can complete this year. The process cannot be short-circuited by political pressure.
70%
The big psilocybin trial will likely show the drug actually works
Compass Pathways' large clinical trial is testing whether a synthetic psilocybin pill can treat depression, and it's expected to hit its main goal — showing the drug works better than a placebo. The trial is nearly finished, the treatment already got a special 'promising' flag from the FDA, and earlier smaller studies showed positive results. If it succeeds, it's a major milestone for turning a psychedelic into a legitimate medicine.
→ The leading psilocybin trial will probably show the drug works — but that's just the beginning of the road to actual approval. (Confidence: 70%)
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
Psilocybin Phase 3 topline hits its primary endpoint in 2026. The trial is ~86% complete with a breakthrough designation and prior supportive Phase 2 data, making statistical success on the primary endpoint the modal outcome even before regulatory interpretation.
68%
Experts will publicly question whether the trial results are trustworthy
Even if the big psilocybin trial shows positive results, scientists and the FDA will likely raise specific concerns. The two main worries: first, people in the trial can usually tell whether they got the real drug (because of the obvious effects), which can skew results. Second, researchers don't yet know how long the benefits last. These are real, unresolved problems with psychedelic research, and a positive result will almost certainly spark a public debate about whether the findings hold up.
→ Expect serious, public scientific debate about whether the trial results can be fully trusted, even if the headline numbers look good. (Confidence: 68%)
Resolves: 2026-12-31 · USA
RESEARCH
the precise call ▾
FDA or independent reviewers publicly flag durability/unblinding concerns about the 2026 psilocybin Phase 3 result. Functional unblinding and durability of effect are unresolved methodological issues in psychedelic trials; a positive readout will almost certainly draw explicit expert critique on these grounds in regulatory commentary or peer review.